A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

NCT07040644 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Neoplasms

Interventions

DRUG: Sacituzumab Govitecan (SG)
DRUG: Toripalimab
DRUG: Nab-paclitaxel

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University